| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | QTTB | Common Stock | Sale | $6,488 | -268 | -9.4% | $24.21* | 2,596 | 25 Mar 2024 | Direct | F1, F2 |
Paul Alloway is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of the RSUs. |
| F2 | On March 25, 2024, the Issuer effected a 1-for-18 reverse stock split (the "Reverse Stock Split"). The share counts herein have been adjusted to reflect the Reverse Stock Split. |
Former President and Chief Operating Officer of Homology Medicines, Inc.